News
ANIP
78.25
-5.30%
-4.38
ANI Pharmaceuticals price target lowered to $90 from $91 at Canaccord
TipRanks · 11m ago
Weekly Report: what happened at ANIP last week (0803-0807)?
Weekly Report · 1h ago
ANI Pharmaceuticals Slides After Lowering FY26 Guidance for Cortrophin Gel Revenue
Dow Jones · 2d ago
ANI Pharmaceuticals Posts Record Q2 2026 Results
TipRanks · 2d ago
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
NASDAQ · 2d ago
ANI Pharmaceuticals, Inc. Profit Climbs In Q2
NASDAQ · 3d ago
ANI Pharmaceuticals backs FY26 revenue view $1.08B-$1.14B, consensus $1.12B
TipRanks · 3d ago
ANI Pharmaceuticals backs FY26 adjusted EPS view $9.19-$9.69, consensus $9.42
TipRanks · 3d ago
ANI Pharmaceuticals Non-GAAP EPS of $2.21 beats by $0.17, revenue of $266.04M beats by $5.91M
Seeking Alpha · 3d ago
*ANI Pharmaceuticals Backs 2026 Rev $1.08B-$1.14B >ANIP
Dow Jones · 3d ago
Press Release: ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
Dow Jones · 3d ago
Press Release: ANI Pharmaceuticals Reports Record -3-
Dow Jones · 3d ago
Press Release: ANI Pharmaceuticals Reports Record -5-
Dow Jones · 3d ago
*ANI Pharmaceuticals 2Q Rev $266M >ANIP
Dow Jones · 3d ago
*ANI Pharmaceuticals 2Q EPS $1.05 >ANIP
Dow Jones · 3d ago
*ANI Pharmaceuticals 2Q Adj EPS $2.21 >ANIP
Dow Jones · 3d ago
ANI Pharmaceuticals’s (NASDAQ:ANIP) Q2 CY2026 Sales Beat Estimates But Stock Drops On Weak Guidance
Barchart · 3d ago
Here are the major earnings before the open Friday
Seeking Alpha · 3d ago
ANI Pharmaceuticals Q2 2026 Earnings Preview
Seeking Alpha · 3d ago
ANI Pharmaceuticals: The Market Is Pricing The Present, Not The Future
Seeking Alpha · 3d ago
More
Webull provides a variety of real-time ANIP stock news. You can receive the latest news about Ani Pharmaceutic through multiple platforms. This information may help you make smarter investment decisions.
About ANIP
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.